Peptide CMC Pre-IND Checklist: ENDO-205 FDA Clearance

Pane wikiwiki

What ENDO-205's FDA clearance does and does not signal, plus a five-pillar peptide CMC pre-IND checklist: kaʻina, haumia, ʻano hana, hana hou.

He aha ka ENDO-205 Clearance e hana a ʻaʻole e haʻi iā ʻoe e pili ana i ka Peptide CMC Pre-IND Manaʻo

kahi manawa maʻalahi e kau ana i ka Malaki 23, 2026 ENDO-205 IND ʻae ʻia ma waena o ka pūʻolo preclinical a me ka Phase i hoʻolālā ʻia 1 e aʻo i ka pre-menop olakino

ʻO ka hana FDA a ENDO-205 he ʻae IND, aole he apono, ʻaʻole ia e ʻōlelo e pili ana i ka pūʻolo CMC ma hope o ia. ʻO Malaki ʻo EndoCyclic 2026 ʻO ka hoʻolaha hoʻolaha IND wehewehe ʻo ia i kahi peptide i hoʻopaʻa ʻia no ka endometriosis, ua pili iā Irvine, Calif., Malaki 23, 2026, me kahi Phase 1 ua hoʻolālā ʻia ke aʻo ʻana i nā wahine pre-menopausal olakino o ka makahiki hānau. Ua ʻōlelo ka hoʻokuʻu like ʻana ua hōʻike ka hana preclinical i ka hoʻopau ʻana i nā ʻeha endometriosis a me nā ʻāʻī pili me ka ʻole o nā hōʻailona palekana i nā haʻawina toxicology GLP.. ʻAʻohe CMC, hana hana, CDMO, a i ʻole nā ​​kikoʻī synthesis o kēlā me kēia ʻano.

ʻO kēlā āpau ke kiko. Hōʻike ka IND i hoʻomaʻemaʻe ʻia iā ʻoe ua hiki ke nānā ʻia kahi pūʻolo no ka hoʻomau; ʻAʻole ia e haʻi iā ʻoe i ka mea i loko, a ʻaʻole ia he laʻana hiki iā ʻoe ke kope. ʻO kahi loiloi kūʻokoʻa o ka mīkini ENDO-205 wehewehe i ke komo ʻana o ke kelepona, ʻO ka peptide pH-sensitive e hui pū ana i ke ala ala Wnt/β-catenin me ka lawe ʻana i ka pH-sensitive, inert i ka pH kino-ola a hana i loko o ka microenvironment lesion acidified. No ke kumu lua wale nō kēlā kikoʻī, ʻaʻole mai ka mea kākoʻo, a ua hōʻike ʻia ke koho i nā hiʻohiʻona preclinical wale nō.

Peptide CMC Pre-IND Checklist: ENDO-205 FDA Clearance

⚠️ ʻŌlelo Aʻo: ʻO ke aniani biospace, ka papa inoa PR Newswire, he mea pharmafile, a me kahi LinkedIn e kaʻana like i ka hoʻokuʻu ʻana i hoʻokahi EndoCyclic. Hoʻokahi kumu lākou, aole eha. ʻAʻohe kumu e uhi ana i ka hoʻomohala ENDO-205 ma hope o Malaki 2026 ua loaa, no laila mālama kēia ʻatikala i ka hanana ma ke ʻano he lā mōʻaukala paʻa.

ʻO ke koena o kēia alakaʻi e hana ma o nā pou ʻelima e hoʻoholo ai inā e hoʻokō ʻia nā koi CMC o kahi peptide IND filing.: hōʻoia kaʻina, hoʻopaʻa ʻana i ka haumia, hōʻoia ʻano analytical method, ka hana hou ʻana, a me nā palapala.

No ke aha ʻo CMC ke kumu maʻamau ʻo Early INDs Stall

Kemika, ʻO ka hana ʻana a me ka hoʻomalu ʻana ke kumu maʻamau loa no kahi paʻa lapaʻau ma kahi IND mua. He loiloi hoʻokele hou o ka FY 2013 Ua loaʻa i ka hui CDER o 1,410 loaʻa nā IND mua i kēlā makahiki, 125, a i ʻole 8.9%, ua hoʻopaʻa ʻia i loko o ka mua 30 lā, a me nā kumu CMC i ʻōlelo pinepine ʻia ma mua o nā kumu lāʻau lapaʻau a i ʻole nā ​​kumu toxicology (ka FDA pilot study ma IND clinical paʻa, paʻi ʻia 2016). E heluhelu i kēlā ma ke ʻano he kumu mōʻaukala ma mua o ka helu o kēia manawa: he loiloi makahiki hoʻokahi o ka pūʻulu hoʻokahi, a ua hoʻololi ʻia nā ʻano paʻa mai ia manawa.

ʻO ka ʻike like ka mea e hiki ai i ka peptide CMC pre-IND ke hana. Ua ʻōlelo ʻo FDA ʻo ka nui o ka ʻike e pono ai "e ʻokoʻa me ka pae o ka hoʻokolokolo, ka hoʻolālā i manaʻo ʻia, a me ka lōʻihi o ka hoʻokolokolo ʻana” (Nā koi ʻike IND CMC o FDA, maʻiʻo i kēia manawa e like me ka 22 Iune 2026). Māhele 1 ʻO ka peptide IND filing CMC koi no laila he scoped set, ʻaʻole ka pūʻolo kalepa piha.

ʻO nā kia ʻelima o ka Peptide CMC Pre-IND mākaukau

Hoʻemi ka peptide CMC pre-IND i nā kia ʻelima, a ʻo ka nīnau pono ʻaʻole ia he mea nui kēlā me kēia akā i ka wā e pau ai. ʻO nā koi ʻike IND CMC o FDA e papa inoa i ʻelima mau mea lāʻau e pono ai ke kākoʻo e hoʻolako: hale a me nā hōʻike ʻike, inoa a me ka helu wahi o ka mea hana, ke ʻano maʻamau o ka hoʻomākaukau ʻana me nā reagents, nā mea hoʻoheheʻe a me nā mea hoʻoheheʻe, nā palena ʻae a me nā ʻano analytical e hoʻokō ai i ka ʻike, ikaika, maikaʻi a me ka maʻemaʻe, a me ke kākoʻo kūpaʻa no ka mālama ʻana a no nā haʻawina toxicological a me ke kauka (FDA, Nā noi IND: ʻIkepili CMC, maʻiʻo i kēia manawa e like me ka 2026-06-22).

Kuhi ʻia kēlā mau mea ʻelima ma luna o nā kia ma lalo. He aha ka hoʻololi ma waena o Phase 1 a he hohonu ka hana hope, ʻaʻole ka papa inoa ponoʻī, no laila, ʻo ka hoʻokaʻawale kūpono ka mea āu e laka ai ma mua o ka hālāwai me ka mea āu e hoʻopanee ai me kahi kumu i kākau ʻia.

Pills

Laka ma mua o ka IND

Hiki ke hoʻopaneʻe ʻia me ke kumu kumu palapala

Hōʻoia kaʻina

ʻO ka hōʻoia ʻana o Orthogonal o ke kaʻina i manaʻo ʻia ma ka ʻāpana lapaʻau

Ka palapala ʻano ʻano ʻano lōʻihi ma waho o ka ʻāpana lapaʻau, me ke kumu no ka hoopuka ana i ka hailona

ʻO ka hoʻopili ʻana i ka haumia

ʻO ka ʻike a me ka helu ʻana o nā mea haumia pili i ka peptide e pili ana i nā paepae pili

ʻO ka hōʻailona toxicological piha o kēlā me kēia haumia i kuhikuhi ʻia, me ke kumu noʻonoʻo e pili ana i ka paepae hōʻoia a me ka ʻike

Nā ʻano kālailai

Nā ʻano hana kūpono me nā pae hoʻoholo ʻae ʻia no ka ʻike, ikaika, maikaʻi a me ka maʻemaʻe

Nā protocols hōʻoia kūpono, me ke kumu noʻonoʻo e hōʻike ana i ka pae-kūpono o ka hoʻonaʻauao ma kēia pae

Ka hana hou ʻana

Nā ʻikepili hoʻohālikelike Lot-to-lot ma nā ʻāpana i hoʻohana ʻia i ka toxicology a me ka lako lapaʻau

Nā lawelawe Hōʻoia kaʻina hana maʻamau a me ka hoʻomau ʻana i ka hōʻoia kaʻina, me ke kumu o ka helu ana o na hailona i hanaia a hiki i keia la

Palapala

ʻO ka moʻolelo CMC a me ka nīnau mua-IND i kākau ʻia

ʻO ka Module piha 3 palapala palapala, me ke kumu noʻonoʻo e pili ana i ka pae pre-IND

ʻO ke kolamu hoʻopaneʻe ka ʻāpana i kākoʻo ma lalo o ka palapala. Pono kēlā me kēia mea i hoʻopaneʻe ʻia i ke kumu i hoʻopaʻa ʻia i loko o ka pūʻolo pōkole ponoʻī, ʻaʻole i mālama ʻia ma nā moʻolelo kūloko, no ka mea, ʻo ka nīnau a ka mea loiloi ma ka hālāwai ke kumu maʻamau ka nele o kahi ʻāpana ʻikepili ma mua o ka loaʻa ʻana..

Pills 1: Ka Hoʻopaʻa ʻana ma mua o ka Halawai Pre-IND

he palapala ʻāina uhi ʻole ʻia e hōʻike ana i nā ʻāpana peptide i hoʻohālikelike ʻia i ke kaʻina holoʻokoʻa me nā wahi i uhi ʻia a wehe ʻole ʻia i kaha ʻia.

Ma ka hopena o kēia kia, pono ʻoe e hoʻopaʻa i kahi kaʻina mua i hoʻopaʻa ʻia i hoʻopaʻa ʻia i kahi ʻāpana kikoʻī, ʻaʻole ka palapala hōʻoia o ka ʻimi wale ʻana. Kāhea ʻia nā koi ʻike IND CMC o FDA no ka wehewehe ʻana i ke kino o ka lāʻau, kemika, a i ʻole nā ​​hiʻohiʻona olaola me nā hōʻike e kākoʻo ana i kona ʻano a me kona ʻano (FDA, kiʻi ʻia 2026-06-22). E nānā i ka hana a kēlā ʻaoʻao: ʻAʻole ia i kapa ʻia he "amino acid sequence" a i ʻole "peptide map,"no laila e kūkulu i kāu hōʻoia peptide sequence ma ke alakaʻi peptide-specific ma kahi. ʻO nā koina ʻae a FDA no nā peptides synthetic e mālama i ke kaʻina kumu ma ke ʻano he nui o nā ana like me nā waiwai physicochemical., hale lua, oligomer a me nā mokuʻāina hoʻohui, a me ka hana olaola (RAPS).

ʻO ke kaʻina hana e māʻona ai i kēia: nuipaʻa paʻa e ka spectrometry nuipa hoʻonā kiʻekiʻe, a laila ka enzymatic a i ʻole ka ʻāpana kemika me LC-MS/MS e hoʻokumu i ka uhi kaʻina ma waena o ke kaulahao piha.. Ma kahi e mau ai nā āpau āpau, e hoʻopaʻa i kēlā mau ʻāpana i ka orthogonally. Laka i ka maʻamau kuhikuhi e pili ana i ka moʻolelo nui i hoʻopaʻa ʻia no laila e hoʻohālikelike ʻia kēlā me kēia ʻāpana hope i kahi heleuma i hōʻike ʻia ma mua o ka hōʻuluʻulu o ka mea kūʻai aku..

⚠️ ʻŌlelo Aʻo: ʻO kahi kaʻina i hōʻoia ʻia e kahi mea kūʻai aku ʻo CoA, me ka loaʻa ʻole o ke ʻano hana maka ma hope hale kūʻai ia, ʻo ia ke ʻano hāʻule. Inā ʻaʻole hiki iā ʻoe ke hana i ka palapala ʻāina uhi, ʻaʻole ʻoe i hōʻoia i ke kaʻina.

Pills 2: ʻO ka hoʻomaʻemaʻe kino a me nā paepae e pili pono ana i nā peptides

Hoʻokaʻawale ʻia nā peptide mai ka ICH Q3A. Hoʻolaha ka Federal Register e hoʻopuka hou ana i ke alakaʻi i nā ʻano lāʻau lapaʻau ʻaʻole i uhi ʻia, a noho ʻo peptide i kēlā papa inoa me nā huahana olaola, oligonucleotides, a me radiopharmaceuticals (ʻO ka wehe ʻana o ka ICH Q3A no nā peptides, 2003-02-11). ʻO ka hopena kūpono ʻo ka hōʻike Q3A, ʻike ʻike, a he papa kuhikuhi no ka papahana peptide, ʻaʻole he koi paʻa, a ʻo ka mālama ʻana i ka haumia peptide e pili ana i ka pilikia.

ʻO ka manaʻo ponoʻī o FDA no nā koina kikoʻī peptide e wehewehe i ke kumu. E like me ka ʻōlelo a RAPS mai ke alakaʻi hope loa, ʻokoʻa i ka haumia, ʻo nā mea haumia pili i ka peptide, hiki ke hoʻopilikia i ka palekana a i ʻole ka maikaʻi o kahi huahana lāʻau peptide i hoʻohālikelike ʻia me ka lāʻau i helu ʻia (ʻO ka ʻae ʻana o FDA no nā peptides synthetic). ʻO ia noʻonoʻo e alakaʻi i nā helu e pono ai ke kākoʻo e hoʻolālā a puni: kahi haumia pili peptide i ʻōlelo ʻia ma mua o 0.5% o ka mea laau, a me kēlā me kēia haumia e pili ana i ka peptide hou i hōʻike ʻia me ka hōʻoia ʻana no ke kumu e hoʻopilikia ai i ka palekana a i ʻole ka hopena e pili ana i ka lāʻau lapaʻau i helu ʻia., me kēlā me kēia haumia i loaʻa i nā pae like a haʻahaʻa paha i ka generic (ʻO ka ʻae ʻana o FDA no nā peptides synthetic).

ʻO nā paepae ICH Q3A iā lākou iho e pili ana i ka dose-band, a ʻoi aku ka maikaʻi o ka mālama ʻia ʻana o ke kāʻei: nā pae hōʻike a me ka ʻike e pili ana i kahi hoʻololi mole liʻiliʻi me ka nui o ka nui o kēlā me kēia lā, no laila, ʻaʻole like ka pākēneka i ka manaʻo like ma nā papahana (ka ICH Q3A hōʻike a me ka ʻike paepae, Q3A(R2), 2006). He kikoʻī a maʻamau ke ʻano hāʻule: haʻi ʻana a 0.10% ka paepae ʻike me he mea lā ua hoʻopaʻa ʻia kahi papahana peptide, a laila e pale ana i kēlā helu ma ka hālāwai pre-IND i ka wā e nīnau ai ka mea loiloi i ke kumu i kūkulu ʻia ai ka hoʻolālā hoʻokele ma luna o kahi alakaʻi e haʻalele i ka mole..

Pills 3: Analytical Methods — Qualification Now, Hooia Mahope

he ala hoʻopaʻa inoa ʻike ʻole, kumu, a me ke kūlana kūpono no kahi mea lāʻau peptide

I ka Phase 1, pono ʻoe i nā ala kūpono me ka palapala kūpono, ʻaʻole i hōʻoia piha ʻia. ʻIke ʻia ka ʻokoʻa ma ka FDA's Phase 1 CMC hikiwawe: manaʻo ka ʻoihana i nā palena ʻae a me nā ʻano analytical e hōʻoia i ka ʻike, ikaika, maikaʻi a me ka maʻemaʻe, me ka wehewehe pōkole o nā ʻano hoʻāʻo i hoʻohana ʻia, e like me ka mea i hōʻike ʻia ma nā koi ʻike IND CMC o FDA. Hōʻoia piha ma lalo o ICH Q2(R2) hiki ke hahai.

Pono ka papahana peptide i ka maʻemaʻe RP-HPLC a i ʻole UHPLC, LC-MS/MS a me HRMS no ka ʻike a me ka ʻano haumia, CE, ka nānā ʻana i ka ʻakika amino, counterion a me ka maʻiʻo TFA, koena solvents, ʻano wai, a me ka endotoxin na LAL. Nā manaʻolana hōʻoia heleuma i ICH Q2(R2); heleuma nā ala endotoxin i ka USP <71> a me USP <85>.

⚠️ ʻŌlelo Aʻo: ʻO ke ʻano hana hoʻomaʻemaʻe me ka hoʻohaʻahaʻa ʻole a i ʻole ka ʻikepili kikoʻī ma hope o ke ʻano o ka hāʻule. ʻO ka hōʻoia me ka ʻole o ka palapala kūpono ʻaʻole ia he kūpono.

Pills 4: Ka Hana Hana Hou a me ka Lot-to-Lot Comparability Narrative

Hōʻike ʻia ka hana hou ʻana ma o ka uhi ʻana i ka ʻikepili nui ma ka liʻiliʻi o ʻekolu mau ʻāpana a hōʻike i ka ʻae ʻana o ka haumia a me nā ʻaoʻao assay., ʻaʻole ma ka ʻōlelo ʻana ua hoʻomalu ʻia ke kaʻina hana. ʻO kahi mea kākoʻo nāna i ʻōlelo "hiki ke hana hou ʻia ke kaʻina hana" me ka ʻole o ka uhi ʻana ua koi ʻo ia ʻaʻole hiki i ka mea loiloi ke nānā..

ʻO ka makau hoʻoponopono ke ʻano maʻamau o ka hoʻomākaukau ʻana. Nīnau nā koi ʻike IND CMC o FDA no ka wehewehe ʻana i ke ʻano o ka hoʻomākaukau ʻana me nā reagents, nā mea hoʻoheheʻe a me nā mea hoʻoheheʻe, me ka ʻike kūpaʻa no ka pani ʻana o ka pahu i manaʻo ʻia a no nā haʻawina toxicological a me nā noiʻi lapaʻau. Heluhelu pu, ʻO kēlā mau mea ʻelua he hoʻopaʻapaʻa reproducibility: wehewehe ka wehewehe ʻana i ka mea e noho mau ai, a hōʻike ka ʻikepili hailona i hana ʻia.

Hoʻohuihui Peptide Piʻi i ka hōʻoia ʻana i ke kaʻina i loko o ka moʻolelo like. Hoʻokumu ka ʻikepili kaʻina i ke ʻano o ka mole; ʻO ka uhi ʻana o ka hailona hiki iā ʻoe ke hana hou. Ke hōʻike nei iā lākou ma ke ʻano he hoʻohālikelike hoʻohālikelike, ma mua o ʻelua mau mea pili kaʻawale, ʻo ia ka mea e pani ai i ka hae pinepine o nā mea loiloi.

He kikoʻī ke ʻano hāʻule. Hiki i ʻekolu mau hailona ke hele pakahi a ʻokoʻa ko lākou haumia i kahi haumia i kuhikuhi ʻia, e haʻi ana i ka mea loiloi ʻaʻole i hoʻomalu ʻia ke kaʻina hana ʻoiai ʻaʻohe ʻāpana i haki i ka palena. ʻO ka 0.5% ʻO ka palena haumia i ʻōlelo ʻia he kaupaku, ʻaʻole he pahuhopu, a me nā koina e ʻae ʻia e FDA no nā peptides synthetic e mālama i nā haumia i ʻōlelo ʻia ma luna o ia me he mea hōʻole ʻole ma mua o ke ʻano o ka nānā ʻana.. E pili ana

He laʻana kūʻokoʻa o ka hana ʻana o kēia ʻikepili: Hāʻawi ʻo MOL Changes i ka peptide synthesis ma ke ʻano i wehewehe ʻia i loko o kahi lumi lumi hoʻomaʻemaʻe, me nā ʻano kālailai ʻO nā Peptides Synthetic e uhi ana i ka hōʻoia ʻana o ke kaʻina a me ka hoʻopili ʻana i ka haumia, no laila hiki mai nā hopena he nui ma ke ʻano he pūʻolo palapala hiki i ke kākoʻo ke hāʻule i ka ʻāpana CMC.

Pills 5: Palapala - Ke kūkulu nei i ka IND CMC Narrative a me ka Pre-IND Question Set

he palapala ʻāina ʻaoʻao hoʻokahi o ka ʻāpana lāʻau lapaʻau IND CMC e hōʻike ana i nā mea i manaʻo ʻia e ka FDA a ʻo wai o nā pou ʻelima e hāʻawi i nā hōʻike no kēlā me kēia.

ʻO ka palapala kahi e hiki ai ke nānā ʻia nā pou ʻehā ʻē aʻe. ʻO ka FDA Nā koi ʻike IND CMC kau i ʻelima mau mea i loko o ka pauku lāʻau lapaʻau: he wehewehe no ka mea laau, me kona kino, kemika, a me nā hiʻohiʻona olaola a me nā hōʻike o ke ʻano; ka inoa a me ka helu wahi o ka mea hana; he ʻano hoʻomākaukau maʻamau; nā palena a me nā ʻano analytical i hoʻohana ʻia e hōʻoia i ka ʻike, ikaika, maikaʻi, a me ka maemae; a me ka ʻikepili kūpaʻa e kākoʻo ana i ke ʻano o ka dosage. E mālama i kēlā papa inoa e like me ke kuamoʻo o kahi papa inoa palapala peptide CMC, a laila palapala ʻāina i kēlā me kēia kia ma luna: Hāʻawi ka hōʻoia ʻana i ke kaʻina hana i nā hōʻike, ʻO ka hoʻopili ʻana i ka haumia e hāʻawi i nā palena, Hāʻawi ka ʻike loiloi i nā ʻano hana, a me ke kaʻina hana reproducibility hāʻawi i ka hailona-i-lot moʻolelo ma hope o ka laulā o ka hoomakaukau ana.

Hoʻonohonoho ʻo FDA i ka hoʻomaʻamaʻa ma ke ʻano he hoʻokahi o ka Phase 1 CMC hikiwawe, ka wehewehe ʻana i ka ʻike liʻiliʻi o nā mea kākoʻo e waiho a me nā mea e hiki ke hahai ma hope. Hōʻike ka ʻaoʻao i ka hoʻopili ʻana me ka helu ʻole ʻana i nā hana i kūpono, no laila e hele mai ka papa inoa hoʻopaneʻe mai ke alakaʻi i hoʻopili ʻia a kākau ʻia i kēlā me kēia mea.

Hoʻopaʻa pū ʻia ka moʻolelo ʻikepili. ʻO ke alakaʻi a me ka wehewehe ʻana i ka pono o ka ʻikepili GxP o MHRA e hoʻonohonoho i nā kumu ALCOA (hiki ke pili, hiki ke heluhelu, hoʻokahi manawa, kumu, pololei) manaʻo ka poʻe loiloi e ʻoluʻolu nā moʻolelo analytical maka.

E lawe mai i kahi nīnau i kākau ʻia i ka hālāwai pre-IND: ʻO nā kikoʻī hiki ke noho manawa, he aha ka lōʻihi paʻa e ʻae ʻia i ka waiho ʻana, inā paha ua lawa ka ʻikepili o ke ʻano pae ʻike, a pehea ka nui o ke ano o ka hoomakaukau ana. Lilo nā pane i kumu kumu i kākau ʻia.

⚠️ ʻŌlelo Aʻo: He pūʻolo e pane ana i nā mea ʻelima a pau akā ʻaʻole hōʻike i nā hana i hoʻopanee ʻia, a no ke aha, ʻo ia ke ʻano hāʻule. Heluhelu nā mea nānā i ka hāmau ma ke ʻano he haʻalele, ʻaʻole like me ka maʻalahi.

Nā hewa maʻamau e hoʻololi i kahi pūʻolo pre-IND i paʻa

ʻO ka hāʻule hou ʻana o ka peptide CMC pre-IND packages ke mālama nei i kahi papa kuhikuhi ma ke ʻano he koi.. ʻElima mau kuhi hewa no ka hapa nui o ka hakakā ʻana.

Ke ʻōlelo nei i nā paepae ICH Q3A me he mea lā ua hoʻopaʻa lākou i kahi papahana peptide. Ua kākau ʻia ʻo ICH Q3A no nā mea lāʻau lāʻau liʻiliʻi, a me kāna hōʻike, ʻAʻole ʻokoʻa ka ʻike a me nā paepae hōʻoia i kahi peptide synthetic. Hiki ke kuhi hewa no ka mea maʻalahi ka loaʻa ʻana o nā helu a maʻalahi hoʻi e pale i loko o kahi memo kūloko. ʻO ka hoʻoponopono ʻana e hōʻike i ka framework āu e noi nei, no ke aha mai, a me ka mea i hōʻike ʻia e kāu ʻikepili pilikino peptide ponoʻī ma kēlā me kēia paepae, ma mua o ka hōʻike ʻana i kahi palena ʻaiʻē i hoʻoholo ʻia.

Hoʻopili i nā koi i nā palapala FDA i loaʻa ʻole iā lākou. Hōʻike mau nā hui i ka "sequence amino acid" a me ka "map peptide" me he mea lā ua papa inoa ka ʻaoʻao IND CMC o FDA iā lākou.. ʻAʻole ia. E nānā i ka ʻaoʻao IND CMC a FDA a ʻaʻole ʻōlelo ma mua o ke komo ʻana o kahi koi i kāu pūʻolo, a lepili i kekahi mea i unuhi ʻia mai ICH, USP a i ʻole nā ​​kulekele kūloko e like me ia.

Paʻi ʻana i nā helu haumia me ka ʻole o ke kumu ʻike ʻia. ʻO nā helu i hōʻoia ʻole ʻia no ka hōʻike ʻana o ka ICH Q3A a me nā paepae ʻike e hoʻolaha nui ʻia i nā hōʻuluʻulu lua.. Inā ʻaʻole hiki iā ʻoe ke wehe i ka palapala kumu a heluhelu i ka helu, e hāʻule a wehewehe paha i ka paepae ma ke ʻano kūpono.

Ka mālama ʻana i ka Phase FDA 1 ʻO nā loli CMC ma ke ʻano he papa inoa hoʻopanee i helu ʻia. Hōʻike kēlā ʻaoʻao i kahi maʻalahi, pae-kupono ala; ʻaʻole ia e hoʻopuka i kahi papa inoa o nā mea āu e hoʻopanee ai. E kūkulu i kāu kumu hoʻopaneʻe ponoʻī a kākau iā ia.

Ke hilinaʻi nei i kahi pūʻulu echo kumu hoʻokahi. ʻO kekahi mau palapala kālepa kālepa o ka EndoCyclic's Malaki 2026 Hoʻolaha hou ka hoʻolaha ʻana o IND me ka ʻole o ka hoʻohui ʻana i nā kikoʻī mua. ʻAʻole hōʻoia ka hana hou ʻana. E hele i ka hoʻolaha ponoʻī a mālama i nā mea āpau ma waho o ia me he mea lā ʻaʻole i hōʻoia ʻia.

⚠️ ʻŌlelo Aʻo: Ua like ke kumu ma hope o nā hewa ʻelima. Kuhi ʻia kahi papa kuhikuhi ma ke ʻano he koi, a ua hoʻoili ka pūʻolo i kahi maʻamau ʻaʻole i koi ʻia ka papahana e hoʻokō.

He aha ka holomua ma ka Halawai Pre-IND

Inā laka ʻia nā kia ʻelima a kākau ʻia kēlā me kēia hoʻopaneʻe me kahi kumu kumu, ʻO ka pūʻolo āu e lawe mai ai i ka hālāwai pre-IND he mea hiki i ka FDA ke loiloi kūʻē i ka pae kūpono kūpono ma mua o ka mea e kono ana i kahi leka CMC hemahema.. ʻElima mau hopena e hana i kēlā paʻa: he kaʻina i hiki ke ʻimi ʻia i ka ʻikepili maka, he moʻolelo haumia me nā palena i ʻōlelo ʻia, nā ala kūpono me ka ʻikepili kūpono i hoʻopili ʻia, kahi uhi hoʻohālikelike ʻekolu-nui, a me kahi moʻolelo e palapala ʻāina i nā mea lāʻau ʻelima e manaʻo ai ka FDA.

ʻO ka ʻaoʻao o ka hōʻea ʻana ma ia ala hiki ke ana, me kahi hōʻailona kūpono e haʻi maʻalahi. Manaʻo ʻo FDA i nā mea kākoʻo o ka Phase mua-i-kanaka 1 Hiki i nā IND ke hōʻemi i ka manawa hoʻomohala noi a hiki i 12 mahina ma ka FDA's Phase 1 CMC hikiwawe, ʻo ke ala ʻike CMC haʻahaʻa kūpono. Nā mea kākau FDA ʻaʻole kūʻokoʻa ke kulekele a me ka kuhi, No laila, e mālama iā ia e like me ka hoʻokumu ʻana o ka ʻoihana ponoʻī i ka hoʻoikaika ʻana ma mua o kahi hōʻailona mai waho.

Kākoʻo ke kuhikuhi o ka huakaʻi i ka heluhelu like. Ua paʻi ʻia ka FDA ka 17 ʻO nā alakaʻi peptide FDA i hoʻoponopono hou ʻia i Iulai 2026 i ka la hookahi, uhi ana i na paepae haumia, hoʻonohonoho kūlana kiʻekiʻe, hana olaola, ka hoʻāʻo ʻana o ka immune immune, a hui hou, synthetic, a me nā ANDA peptide semi-synthetic. Ke hoʻopaʻa ikaika nei ka ʻoihana i kāna mau huaʻōlelo peptide, ʻo ia ka mea e maʻalahi ai ka nānā ʻana i kahi pūʻolo i kākau ʻia ma ia huaʻōlelo.

E like me ka pahu hopu, e hoʻonui i ka moʻolelo hoʻohālikelike āu i kūkulu ai no ka pre-IND e pili ana i ka hoʻolālā hōʻoia ʻana ma hope: ʻo ka uhi ʻana ʻekolu-nui hoʻokahi e lilo i iwi kuamoʻo o kāu Phase 2 a me ka Phase 3 hoʻolālā hōʻoia ʻano, no laila, hui ka hana ma mua o ka hana hou ʻana.

Nīnau pinepine

E haʻi mai ka ʻae ʻana o ENDO-205 IND iaʻu i ka mea i ʻae ʻia e ka pūʻolo CMC FDA?

ʻAʻole. ʻO Malaki ʻo EndoCyclic 2026 Hōʻike ka hoʻolaha ʻae ʻana o IND i ka ʻae ʻana, ka hoailona, ke kumu preclinical a me ka Phase i hoʻolālā ʻia 1 hoʻolālā, a ʻaʻohe CMC, hana hana, CDMO a i ʻole nā ​​kikoʻī synthesis. ʻOi aku ka liʻiliʻi o ka hōʻailona hōʻailona akā pono mau: Hiki ke loiloi ʻia kahi ʻāpana kūpono no kahi peptide synthetic e like me ka waiho ʻana. ʻAʻole ia e haʻi iā ʻoe e pili ana i nā ʻano analytical, nā palena haumia a i ʻole ka hōpili ʻikepili i ʻike ʻia e ka ʻoihana.

E pili ana nā paepae haumia ICH Q3A i nā mea lāʻau peptide?

ʻAʻole. ʻO ka wehe ʻana o ka ICH Q3A no nā peptides e papa inoa i ka peptide i waena o nā mea lāʻau lapaʻau ʻaʻole i uhi ʻia ke alakaʻi haumia.. Noho mau ʻo Q3A i kahi papa kuhikuhi kūpono no ka hoʻonohonoho ʻana i kahi kūkākūkā pili ʻana i ka peptide haumia, akā, ʻaʻole ia ka paepae paʻa i kau ʻia no kāu mea lāʻau. ʻO ka mālama ʻana i ka haumia peptide ma muli o ka pilikia, pili i ke ala synthetic, ka holoi ʻana a me ka ʻoki ʻana i nā kaʻina i hiki ke hana i ke ala, a me ka hōʻailona toxicological o kēlā me kēia haumia i kuhikuhi ʻia. Hana ʻia ʻo Peptide

He aha ka 0.5% uhi maoli ʻia ke kiʻi haumia pili i ka peptide?

He palena haumia e pili ana i ka peptide i hōʻike ʻia mai ka ʻae ʻana o FDA no nā peptides synthetic.. He mea nui nā palena ākea ʻelua. Pili ia i nā mea haumia pili i ka peptide, ʻaʻole i nā mea haumia i ʻike ʻole ʻia, nā mea hoʻoheheʻe koena a i ʻole nā ​​mea haumia, e hahai ana i ko lakou mau papa. A ʻaʻole pono e hoʻonui ʻia i kēlā me kēia ʻano peptide. E hōʻoia i ke kiʻi e pili ana i ka palapala alakaʻi mua ma mua o kou haʻi ʻana i loko o kahi pūʻolo pre-IND.

Pono e hōʻoia piha ʻia nā ʻano analytical ma mua o ka hālāwai pre-IND?

ʻAʻole. ʻO ka pae o FDA 1 Kākoʻo ka CMC flexibilities i ka hōʻailona kūpono i kēia manawa, ʻaʻole hōʻoia piha. ʻO ka mea e pono ai ka pūʻolo hālāwai ʻo ka FDA's IND CMC ʻike pono mea e pili ana i nā palena ʻae a me nā ʻano loiloi: pono ʻoe e hōʻike ua kūpono kēlā me kēia ala no ka hoʻohana ʻana, ua kūpono kona mau palena o ka ʻike a me ka nui no nā paepae haumia āu e koi nei, a hiki iā ʻoe ke wehewehe i ka hana koʻikoʻi āu i hana ai. Loaʻa ka hōʻoia piha ma hope, ma mua o ke kākoʻo ʻana o nā ʻano i ka hoʻāʻo hoʻokuʻu ʻana no ka lako lapaʻau.

He aha inā hāʻule ka hōʻoia ʻana o ke kaʻina ma ka hailona mua?

E mālama iā ia he pilikia ala, ʻaʻole pilikia palapala. ʻO ka hāʻule ʻana o ka hoʻopaʻa ʻana i ke kaʻina ma ka hailona mua e kuhikuhi pinepine i kahi hui, deprotection a i ʻole ka hana hoʻomaʻemaʻe ʻaʻole i hoʻomalu ʻia, a ʻo ka hoʻoponopono ʻana he hana kaʻina hana ma mua o ka palapala hōʻoia kākau hou ʻana. E holo hou i ka hōʻoia ma ka hailona hou ma hope o kou ʻike ʻana i ka ʻanuʻu, a palapala i ka hemahema a me ka hana hooponopono. ʻOi aku ka ikaika o kahi pūʻolo pre-IND e hōʻike ana iā ʻoe i loaʻa a pani ʻia ka ʻāpana ma mua o ka mea e hōʻike ana i ka hala wale ʻana o ka hailona..

Nā ʻanuʻu aʻe

I kēia manawa he puka puka kāu, ʻO ka papa inoa palapala peptide CMC kūpono i ka pae ma nā kia ʻelima: hōʻoia kaʻina, hoʻopaʻa ʻana i ka haumia, hōʻoia ʻano analytical method, ka hana hou ʻana, a me ka moʻolelo IND ponoʻī. ʻO ka maʻamau e hoʻopaʻa iā ʻoe iho ʻo ia ka palena palena kūpono, a me ka manaʻo o ka FDA a hiki i 12 ʻO nā mahina i hoʻemi ʻia ka manawa hoʻomohala noi ke kumu o ia (FDA, kiʻi ʻia 2026-06-09). E nānā i ka laulā: Nā mea kākau FDA i kēlā kulekele, no laila ʻaʻole kūʻokoʻa ka manaʻo. Ke kau ʻia ka uhi hoʻohālikelike ʻekolu-nui, ʻO ka pahuhopu maoli ka hoʻonui ʻana i ka hoʻolālā hōʻoia hope.

Ki Takeaway: ʻElima kia, ʻelima mau mea hana i hōʻoia ʻia: he kaʻina hiki ke ʻimi ʻia i ka puka ʻana o ke ʻano maka, he moʻolelo haumia me nā palena i ʻōlelo ʻia, nā ala kūpono me ka ʻikepili kūpono, kahi uhi hoʻohālikelike ʻekolu-nui, a me kahi moʻolelo i paʻi ʻia ma luna o nā mea lāʻau lāʻau ʻelima a FDA. Inā nalo kekahi o ia mau mea, ʻo ia ka hakahaka e pani ai ma mua o ka hālāwai pre-IND.

E lawe mai i ka pūʻolo, aole na ninau. Hoʻopuka a palapala ʻo MOL Changes i ka ʻikepili analytical level lot no ka mea lāʻau peptide, me ka hōʻoia ʻana o ke kaʻina, hoʻopaʻa ʻana i ka haumia, ʻano kūpono, a me ka hoʻohālikelike ʻana me ka hailona, me ka synthesis mai milligrams a hiki i kilokani ma ka Papa 100 hana lumi maʻemaʻe a me HPLC, MS, a me ka ho'āʻo sterility. E kamaʻilio me kahi loea, a i ʻole e noi i ka pūʻolo ʻikepili hailona.

Hoʻopuka ʻo MOL Changes ma ke ʻano he mea kūʻai peptide a loaʻa iā ia kahi hoihoi pāʻoihana i nā kūlana maikaʻi peptide. ʻAʻole kēia ʻatikala he ʻōlelo aʻoaʻo hoʻoponopono; Pono nā mea kākoʻo e hōʻoia i nā koi me ka FDA a nīnau i nā ʻoihana hoʻoponopono kūpono.

Jinling Liu

Jinling Liu

Kaʻina hana R&D a me ka Mea Hana Hana Kaʻike kumu: Hoʻonui kaʻina hana, kemika ʻōmaʻomaʻo, hoʻomaikaʻi maikaʻi, Hoʻokō ka hana GMP.

Pilikino: He loea ʻo Jinling Liu i ka unuhi ʻana o nā lāʻau peptide mai ka pālākiō keʻena (pae milligram) i ka hana pāʻoihana (pae kilokani). Ua kūpaʻa ʻo ia i ka hōʻemi nui ʻana i nā kumukūʻai hana peptide a me ka hōʻemi ʻana i ka pollution kaiapuni ma o ka hoʻonui ʻana i nā kūlana cleavage., ka hoʻomaikaʻi ʻana i nā lakio o nā condensation reagents, a me ka hoʻolauna ʻana i ka ʻenehana synthesis kahe mau. Ua alakaʻi ʻo ia i ka optimization o nā papahana peptide he nui, ka loaʻa ʻana o ke kumu kūʻai haʻahaʻa, hoʻomaʻemaʻe kiʻekiʻe ma ka pālākiō 100-kilogram.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana